



Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results

May 13, 2008

- LUVOX(R) CR Approved and Launched
- Screening Closed in First Phase III Fibromyalgia Clinical Trial

PALO ALTO, Calif., May 13 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the quarter ended March 31, 2008.

Total revenues for the quarter ended March 31, 2008 were \$14.6 million, compared to \$14.1 million for the quarter ended March 31, 2007. XYREM(R) (sodium oxybate oral solution) net sales for the first quarter of 2008 increased 32 percent to \$11.3 million, compared with \$8.6 million for the first quarter of 2007.

Once-Daily LUVOX CR(R) (fluvoxamine maleate) Extended-Release Capsules was approved by the U.S. Food and Drug Administration (FDA) on February 28, 2008 for the treatment of both obsessive compulsive disorder (OCD) and social anxiety disorder (SAD), and the product was shipped to wholesalers late in the first quarter.

"The launch of LUVOX CR in the U.S. is progressing very well," said Robert Myers, President of Jazz Pharmaceuticals. "Our commercial team is focused on introducing this important new treatment option to physicians for their patients with OCD and SAD."

"We are off to a great start in 2008, with significant product development achievements in addition to our commercial success," said Samuel Saks, M.D., Chief Executive Officer. "We recently completed screening of subjects in the first of our Phase III pivotal studies of JZP-6 for the treatment of fibromyalgia syndrome, a key milestone in this program. We look forward to obtaining results from this Phase III trial in the fourth quarter of 2008."

Research and development expenses for the first quarter of 2008 were \$21.2 million, compared to \$14.9 million for first quarter of 2007. The increase primarily reflects higher expenses associated with later stage development programs, particularly JZP-6.

Selling, general and administrative expenses for first quarter of 2008 were \$32.8 million, compared to \$14.3 million for the first quarter of 2007. The increase was primarily due to spending in preparation for the launch of LUVOX CR, increased headcount and higher expenses to support the larger sales force.

Net loss for the first quarter of 2008 was \$46.7 million, compared to a \$19.6 million net loss for the first quarter of 2007.

Jazz Pharmaceuticals' unrestricted cash and marketable securities balance as of March 31, 2008 was \$105.2 million. During the quarter ended March 31, 2008, net cash used in operating activities was \$38.2 million.

Recent Highlights

- In late March 2008, approximately \$3.0 million of LUVOX CR commercial product was shipped to wholesalers. As is common for new pharmaceutical product launches, no LUVOX CR net sales revenue was recognized in the first quarter of 2008.
- In mid-April 2008, Jazz Pharmaceuticals' sales team of approximately 200 field-based professionals began communicating with psychiatrists and select primary care physicians about the unique attributes of LUVOX CR for OCD and SAD patients. Sales professionals are providing samples of LUVOX CR in 100 mg and 150 mg doses. Jazz Pharmaceuticals is also supporting non-branded disease awareness campaigns to highlight the importance of correctly diagnosing and treating OCD and SAD.
- Approval and launch of LUVOX CR triggered a total of \$41.0 million in milestone payments to Solvay Pharmaceuticals, \$10.0 million of which was paid in March 2008.
- On April 25, 2008, screening of subjects was closed in the first of Jazz Pharmaceuticals' two Phase III clinical trials of JZP-6 (sodium oxybate) in fibromyalgia. The enrollment goal of 525 subjects has been achieved in the first trial, and enrollment is expected to be completed in the next several weeks. Top-line results for the first trial are expected in the fourth quarter of 2008. Enrollment is progressing in the second Phase III clinical trial of JZP-6 at clinical sites in the U.S. and Europe.
- On March 18, 2008, Jazz Pharmaceuticals announced the expansion of its senior term debt under an agreement with an affiliate of Lehman Brothers and certain other lenders. The transaction closed with \$40 million of gross proceeds, expanding the senior debt outstanding from \$80 million to \$120 million. Jazz Pharmaceuticals has an option under the agreement, through January 31, 2009, to borrow an additional \$30 million if sales of the company's products reach certain levels by the end of 2008.
- On May 8, 2008, Jazz Pharmaceuticals announced it had entered into a Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Limited, a private investment group, in which Kingsbridge committed to provide up to \$75 million of capital through the purchase of newly-issued shares of Jazz Pharmaceuticals' common stock. Under the terms of the three-year agreement, Jazz Pharmaceuticals will determine the exact timing and amount of any CEFF financings, subject

JAZZ PHARMACEUTICALS, INC.
SUMMARY OF PRODUCT SALES, NET
(In thousands)
(Unaudited)

	Three Months Ended March 31,	
	2008	2007
Xyrem	\$11,341	\$8,624
Antizol	2,643	2,636
Cystadane	-	365
Total	\$13,984	\$11,625

JAZZ PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)

	March 31, 2008	December 31, 2007
ASSETS		
Current assets:		
Cash and cash equivalents	\$100,771	\$102,945
Restricted cash	1,998	1,939
Marketable securities	4,410	-
Accounts receivable, net	5,310	5,389
Inventories	2,200	2,213
Prepaid expenses	3,210	3,224
Other current assets	1,346	381
Total current assets	119,245	116,091
Property and equipment, net	3,875	3,941
Intangible assets, net	74,919	36,040
Goodwill	38,213	38,213
Long-term restricted cash and investments	-	12,000
Other long-term assets	2,766	1,269
Total assets	\$239,018	\$207,554
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Line of credit	\$3,180	\$3,459
Accounts payable	8,915	2,856
Accrued liabilities	30,133	29,047
Purchased product rights liability	31,000	-
Deferred revenue	1,494	1,494
Total current liabilities	74,722	36,856
Non-current portion of deferred revenue	12,183	12,468
Liability under government settlement	13,063	14,881
Senior secured notes	113,367	75,116
Common stock subject to repurchase	13,241	13,241
Stockholders' equity	12,442	54,992
Total liabilities and stockholders' equity	\$239,018	\$207,554

SOURCE Jazz Pharmaceuticals, Inc.

CONTACT: Matthew Fust, Chief Financial Officer of Jazz Pharmaceuticals, Inc., +1-650-496-2800, investorinfo@jazzpharmaceuticals.com; or Karen L. Bergman, +1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners for Jazz Pharmaceuticals, Inc.
Web site: <http://www.jazzpharmaceuticals.com>